References
- Van Dyk J. J., Falkson H. C., Van der Merwe A. M., Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Research 1972; 32: 921–924
- Meanwell C. A., Blake A. E., Blackledge G. Encephalopathy associated with ifosfamide/mesna therapy. Lancet 1985; i: 406–407
- Meanwell C. A., Blake A. E., Kelly K. A., Honigsberger L., Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur. J. Cancer Clin. Oncol 1986; 7: 815–819
- Pratt C. B., Green A. A., Horowitz M. C. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J. Clin. Oncol 1986; 4: 1253–1261
- Gieron M. A., Barak L. S., Estrada J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J. Neuro. Oncol 1988; 6: 29–30
- Meanwell C. A., Kelly K. A., Blackledge G. Avoiding ifosfamide/mesna encephalopathy. Lancet 1986; i: 406
- Perren T. J., Turner R. C., Smith I. E. Encephalopathy with rapid infusion of ifosfamide/mesna. Lancet 1987; i: 390–391
- Goren M. P., Wright R. N., Pratt C. B., Pell F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; ii: 1219–1220
- Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin. Oncol 1982; 9: 2–7
- Heim M. E., Feine R., Schick E., Wolpert E., Quisser W. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J. Cancer Res. Clin. Oncol 1981; 100: 113–116